Understanding factors in burn patient follow-up

2021 ◽  
Author(s):  
Eve A Solomon ◽  
Elizabeth Phelan ◽  
Lilia G Tumbaga ◽  
Irina P Karashchuk ◽  
David G Greenhalgh ◽  
...  
Keyword(s):  
Substance Use ◽  
Drug Users ◽  
Discharge Planning ◽  
Univariate Analysis ◽  
Retrospective Chart Review ◽  
Multivariate Regression Analysis ◽  
Missed Appointments ◽  
Factors Associated ◽  
Injured Patients

Abstract Follow-up rates (FUR) are concerningly low among burn-injured patients. This study investigates the factors associated with low FUR and missed appointments (MA). We hypothesize that patients who are homeless, use illicit substances, and have psychiatric comorbidities will have lower rates of follow-up (FU) and more MAs. Data from a discharge-planning survey of 281 burn-injured patients discharged from September 2019 – July 2020 was analyzed and matched with patients’ EMR records for a retrospective chart review. Data collected included general demographics, burn characteristics, hospitalization details, FU visits, MAs, homeless status, substance use, major psychiatric illness (MPI), and survey responses. Data analysis used Chi-square, Fisher’s exact test, Student t-test, Wilcox Rank Sum test, and Multivariate Regression Analysis (MVR). Overall, 37% of patients had no FU in clinic and 46% had one or more MA. On MVR, homeless patients were more likely to never follow up, OR = 0.227 (95% CI = 0.106-0.489), as were patients who anticipated transportation difficulties, OR = 0.275 (95% CI = 0.151-0.501). Homeless patients were more likely to have MA, OR= 0.231 (95% CI = 0.099-0.539). On univariate analysis, patients with one or more documented MPI had lower FUR, with 50.62% having no FU (p = 0.0020). Among patients who responded to the survey that they were current drug users, 52% had no FU as compared to 28% of patients who responded that they did not use drugs (p = 0.0007). Factors associated with lower FUR and more MAs include homeless status, substance use, MPI, and transportation difficulties.

Predictive Clinical and Surgical Factors Associated with Recurrent Apoplexy in Pituitary Adenomas

2021 ◽  
Author(s):  
Alan Siu ◽  
Sanjeet Rangarajan ◽  
Michael Karsy ◽  
Christopher J. Farrell ◽  
Gurston Nyquist ◽  
...  
Keyword(s):  
Pituitary Apoplexy ◽  
Radiation Treatment ◽  
Univariate Analysis ◽  
Rare Event ◽  
Retrospective Chart Review ◽  
Subtotal Resection ◽  
Cavernous Sinus Invasion ◽  
Factors Associated ◽  
Increased Risk

Abstract Introduction Pituitary apoplexy is an uncommon clinical condition that can require urgent surgical intervention, but the factors resulting in recurrent apoplexy remain unclear. The purpose of this study is to determine the risks of a recurrent apoplexy and better understand the goals of surgical treatment. Methods A retrospective chart review was performed for all consecutive patients diagnosed and surgically treated for pituitary apoplexy from 2004 to 2021. Univariate analysis was performed to identify risk factors associated with recurrent apoplexy. Results A total of 115 patients were diagnosed with pituitary apoplexy with 11 patients showing recurrent apoplexy. This occurred at a rate of 2.2 cases per 100 patient-years of follow-up. There were no major differences in demographic factors, such as hypertension or anticoagulation use. There were no differences in tumor locations, cavernous sinus invasion, or tumor volumes (6.84 ± 4.61 vs. 9.15 ± 8.45 cm, p = 0.5). Patients with recurrent apoplexy were less likely to present with headache (27.3%) or ophthalmoplegia (9.1%). Recurrent apoplexy was associated with prior radiation (0.0 vs. 27.3%, p = 0.0001) and prior subtotal resection (10.6 vs. 90.9%, p = 0.0001) compared with first time apoplexy. The mean time to recurrent apoplexy was 48.3 ± 76.9 months and no differences in overall follow-up were seen in this group. Conclusion Recurrent pituitary apoplexy represents a rare event with limited understanding of pathophysiology. Prior STR and radiation treatment are associated with an increased risk. The relatively long time from the first apoplectic event to a recurrence suggests long-term patient follow-up is necessary.

2 Rates of Follow up After Burn Injury Are Disturbingly Low and Linked with Social Factors

2021 ◽  
Vol 42 (Supplement_1) ◽  
pp. S7-S7
Author(s):  
Irina P Karashchuk ◽  
Eve A Solomon ◽  
David G Greenhalgh ◽  
Soman Sen ◽  
Tina L Palmieri ◽  
...  
Keyword(s):  
Low Socioeconomic Status ◽  
Drug Dependence ◽  
Burn Injury ◽  
Retrospective Chart Review ◽  
Missed Appointments ◽  
Poverty Level ◽  
Logistic Regression Models ◽  
Factors Associated ◽  
Burn Center

Abstract Introduction Due to risks of scarring and difficulties with re-socialization, it is important that burn patients attend follow up appointments to minimize adverse sequelae. Studies in trauma and emergency medicine have shown a correlation between reduced follow up and low socioeconomic status. Our goal was to examine the factors leading to missed follow up appointments in the burn center population. Methods Following IRB approval, a retrospective chart review was conducted using electronic medical records of all adult patients admitted to the burn center from 2016–2018. Data collected included information on burn injury, social status, substance use, and zip code demographics. Exclusions included patients with non-burn injuries, who died in the hospital, who were transferred to another hospital, who did not have any scheduled outpatient follow up, who had insurance which precluded follow up at our institution, and prisoners. Data analysis was conducted using chi-square, t-test, linear, and logistic regression models. Results A total of 878 patients (mean age 45.1 ± 16.8 years, 646 males (73.6%), mean burn size (TBSA) 10.16±11.7%) were analyzed. In our population, 96 (10.93%) patients were homeless, 284 (32.35%) had drug dependence, 128 (14.58%) had alcoholism, and the mean poverty level was 17.7±8.34%. Of those analyzed, 224 (25.5%) failed to attend any follow up appointments and 492 (56.0%) had at least one missed appointment. Patients who did not attend any follow up appointments had smaller burns (8.2±9.5% vs. 10.8±12.3%), traveled farther (91.8±101.1 miles vs. 69.0±68.7 miles), were more likely to be homeless (22.8% vs. 6.9%) and to have drug dependence (47.3% vs. 27.2%). Patients who missed at least one appointment were younger (43.8±16.1vs. 46.8±17.4 years), more likely to be homeless (17.5% vs. 2.6%) and have drug dependence (42.5% vs. 19.4%). On multivariate analysis, factors associated with never returning to clinic were: Distance from hospital (odds ratio (OR) 1.004, p=0.0001), TBSA (OR 0.96, p= 0.0001), Drug Dependence (OR 0.49, p< 0.0001), and Homelessness (OR 0.31, p< 0.0001). Factors associated with missing at least one appointment were: Age (OR 0.99 p< 0.03), Drug Dependence (OR 0.51, p< 0.0001), Homelessness (OR 0.20, p< 0.0001), and ED visits (OR 0.57, p< 0.05). Conclusions In our population, a high percentage of patients fail to make any appointment following their injury and an even higher number miss at least one appointment. The factors that influence failure to return and missing at least one appointment are similar but not exactly the same. Both follow up and missed appointments are influenced by social determinants of health.

scholarly journals POS1234 IMPACT OF THE CHANGE IN ADMINISTRATION ROUTE OF TOCILIZUMAB AND ABATACEPT, DUE TO THE COVID-19 LOCKDOWN ON DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 900.1-900
Author(s):  
L. Diebold ◽  
T. Wirth ◽  
V. Pradel ◽  
N. Balandraud ◽  
E. Fockens ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Physical Activity ◽  
Disease Activity ◽  
Univariate Analysis ◽  
Route Of Administration ◽  
Anxiety And Depression ◽  
Administration Route ◽  
Factors Associated ◽  
The Impact

Background:Among therapeutics used to treat rheumatoid arthritis (RA), Tocilizumab (TCZ) and Abatacept (ABA) are both biologic agents that can be delivered subcutaneously (SC) or intravenously (IV). During the first COVID-19 lockdown in France, all patients treated with IV TCZ or IV ABA were offered the option to switch to SC administration.Objectives:The primary aim was to assess the impact of changing the route of administration on the disease activity. The second aim was to assess whether the return to IV route at the patient’s request was associated with disease activity variation, flares, anxiety, depression and low physical activity during the lockdown.Methods:We conducted a prospective monocentric observational study. Eligibility criteria: Adult ≥ 18 years old, RA treated with IV TCZ or IV ABA with a stable dose ≥3 months, change in administration route (from IV to SC) between March 16, 2020, and April 17, 2020. The following data were collected at baseline and 6 months later (M6): demographics, RA characteristics, treatment, history of previous SC treatment, disease activity (DAS28), self-administered questionnaires on flares, RA life repercussions, physical activity, anxiety and depression (FLARE, RAID, Ricci &Gagnon, HAD).The primary outcome was the proportion of patients with a DAS28 variation>1.2 at M6. Analyses: Chi2-test for quantitative variables and Mann-Whitney test for qualitative variables. Factors associated with return to IV route identification was performed with univariate and multivariate analysis.Results:Among the 84 patients who were offered to switch their treatment route of administration, 13 refused to change their treatment. Among the 71 who switched (48 TCZ, 23 ABA), 58 had a M6 follow-up visit (13 lost of follow-up) and DAS28 was available for 49 patients at M6. Main baseline characteristics: female 81%, mean age 62.7, mean disease duration: 16.0, ACPA positive: 72.4%, mean DAS28: 2.01, previously treated with SC TCZ or ABA: 17%.At M6, the mean DAS28 variation was 0.18 ± 0.15. Ten (12.2%) patients had a DAS28 worsening>1.2 (ABA: 5/17 [29.4%] and TCZ: 5/32 [15.6%], p= 0.152) and 19 patients (32.8%) had a DAS28 worsening>0.6 (ABA: 11/17 [64.7%] and TCZ: 8/32 [25.0%], p= 0.007).At M6, 41 patients (77.4%) were back to IV route (26 TCZ, 15 ABA) at their request. The proportion of patients with a DAS28 worsening>1.2 and>0.6 in the groups return to IV versus SC maintenance were 22.5%, 42.5% versus 11.1% and 22.2% (p=0.4), respectively. The univariate analysis identified the following factors associated with the return to IV route: HAD depression score (12 vs 41, p=0.009), HAS anxiety score (12 vs 41, p=0.047) and corticosteroid use (70% vs 100%, p=0.021), in the SC maintenance vs return to IV, respectively.Conclusion:The change of administration route of TCZ and ABA during the first COVID-19 lockdown was infrequently associated with a worsening of RA disease. However, the great majority of the patients (77.4%) request to return to IV route, even without disease activity worsening. This nocebo effect was associated with higher anxiety and depression scores.Disclosure of Interests:None declared

Follow up after burn injury is disturbingly low and linked with social factors

2021 ◽  
Author(s):  
Irina P Karashchuk ◽  
Eve A Solomon ◽  
David G Greenhalgh ◽  
Soman Sen ◽  
Tina L Palmieri ◽  
...  
Keyword(s):  
Social History ◽  
Drug Dependence ◽  
Burn Injury ◽  
Retrospective Chart Review ◽  
Burn Patients ◽  
Chi Square ◽  
Factors Associated ◽  
Ed Visits ◽  
Zip Code

Abstract For medical and social reasons, it is important that burn patients attend follow up appointments (FUAs). Our goal was to examine the factors leading to missed FUAs in burn patients. A retrospective chart review was conducted of adult patients admitted to the burn center from 2016-2018. Data collected included burn characteristics, social history, and zip code. Data analysis was conducted using chi-square, Wilcox Rank Sum tests, and multivariate regression models. A total of 878 patients were analyzed, with 224 (25.5%) failing to attend any FUAs and 492 (56.0%) missing at least one appointment (MA). Patients who did not attend any FUAs had smaller burns (4.5 (8)% vs. 6.5 (11)% median (inter quartile range)), traveled farther (70.2 (111.8) vs. 52.5 (76.7) miles), and were more likely to be homeless (22.8% vs. 6.9%) and have drug dependence (47.3% vs. 27.2%). Patients who had at least one MA were younger (42 (26) vs. 46 (28) years) and more likely to be homeless (17.5% vs. 2.6%) and have drug dependence (42.5% vs. 19.4%). On multivariate analysis, factors associated with never attending a FUA were: distance from hospital (odds ratio (OR) 1.004), burn size (OR 0.96), and homelessness (OR 0.33). Factors associated with missing at least one FUA : age (OR 0.99), drug dependence (OR 0.46), homelessness (OR 0.22), and ED visits (OR 0.56). A high percentage of patients fail to make any appointment following their injury and/or have at least one MA. Both FUAs and MAs are influenced by social determinants of health.

MO282EARLY RENAL RECOVERY AFTER A FIRST FLARE OF PAUCI IMMUNE GLOMERULONEPHRITIS

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Jeremy Zaworski ◽  
Cyrille Vandenbussche ◽  
Pierre Bataille ◽  
Eric Hachulla ◽  
Francois Glowacki ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Interstitial Fibrosis ◽  
Univariate Analysis ◽  
Renal Recovery ◽  
Neurological Involvement ◽  
Factors Associated ◽  
Stage Renal Disease ◽  
End Stage

Abstract Background and Aims Renal involvement is a severe manifestation of ANCA-associated vasculitis. Patients often progress to end-stage renal disease. The potential for renal recovery after a first flare has seldom been studied. Our objectives were to describe the evolution of the estimated glomerular filtration rate (eGFR) and identify factors associated with the change in eGFR between diagnosis and follow-up at 3 months (ΔeGFRM0–M3) in a cohort of patients with a first flare of pauci-immune glomerulonephritis. Methods This was a retrospective study over the period 2003–2018 of incident patients in the Nord-Pas-de-Calais (France). Patients were recruited if they had a first histologically-proven flare of pauci immune glomerulonephritis with at least 1 year of follow up. Kidney function was estimated with MDRD-equation and analysed at diagnosis, 3rd, 6th and 12th months. The primary outcome was ΔeGFRM0–M3. Factors evaluated were histological (Berden classification, interstitial fibrosis, percentage of crescents), clinical (extra-renal manifestations, sex, age) or biological (severity of acute kidney injury, dialysis, ANCA subtype). Results One hundred and seventy-seven patients were included. The eGFR at 3 months was significantly higher than at diagnosis (mean ± standard deviation, 40 ± 24 vs 28 ± 26 ml/min/1.73 m2, p < 0.001), with a ΔeGFRM0–M3 of 12 ± 19 ml/min/1.73 m2. The eGFR at 12 months was higher than at 3 months (44 ± 13 vs 40 ± 24 ml/min/1.73m2, p = 0.003). The factors significantly associated with ΔeGFRM0–M3 in univariate analysis were: sclerotic class according to Berden classification, percentage of interstitial fibrosis, percentage of cellular crescents, acute tubular necrosis, neurological involvement. The factors associated with ΔeGFRM0–M3 in multivariate analysis were the percentage of cellular crescents and neurological involvement. The mean increase in eGFR was 2.90 ± 0.06 ml/min/1.73m2 for every 10-point gain in the percentage of cellular crescents. ΔeGFRM0–M3 was not associated with the risks of end-stage renal disease or death in long-term follow-up. Conclusions Early renal recovery after a first flare of pauci-immune glomerulonephritis occurred mainly in the first three months of treatment. The percentage of cellular crescents was the main independent predictor of early renal recovery.

Patient-Related Risk Factors Associated With Surgical Site Complications After Elective Hand Surgery

Hand ◽  
2020 ◽  
pp. 155894472094426
Author(s):  
Tyler Youngman ◽  
Michael Del Core ◽  
Timothy Benage ◽  
Daniel Koehler ◽  
Douglas Sammer ◽  
...  
Keyword(s):  
Risk Factors ◽  
Regression Analysis ◽  
Surgical Complications ◽  
Multivariate Regression ◽  
Univariate Analysis ◽  
Hand Surgery ◽  
Multivariate Regression Analysis ◽  
Class Iii ◽  
Factors Associated ◽  
Surgical Site Complications

Background: The purpose of this study was to identify independent risk factors associated with an increased rate of surgical site complications after elective hand surgery. Methods: This study is a retrospective review of all patients who underwent elective hand, wrist, forearm, and elbow surgery over a 10-year period at a single institution. Electronic medical records were reviewed, and information regarding patient demographics, past medical and social history, perioperative laboratory values, procedures performed, and surgical complications was collected. Surgical site complications included surgical site infections, seromas or hematomas, and delayed wound healing or wound dehiscence. A univariate analysis was then performed to identify potential risk factors, which were then included in a multivariate regression analysis. Results: A total of 3261 patients who underwent elective hand surgery and met the above inclusion and exclusion criteria were included in this study. The mean age was 57 years, with 65% female and 35% male patients. The overall surgical complication rate was 2.2%. Univariate analysis of patient factors identified male sex; number of procedures >1; history of drug, alcohol, or smoking use; American Society of Anesthesiologists (ASA) class III and IV; and serum albumin <3.5 mg/dL to be significantly associated with complications. However, multivariate regression analysis identified that only ASA class III and IV (odds ratio = 3.27) was significantly associated with surgical complications. Conclusions: Patients classified as ASA class III or IV were identified to be at a significantly increased risk of complications following elective hand surgery. Health factors which triage patients into these 2 groups may represent potentially modifiable factors to mitigate perioperative risk in the elective hand surgery population.

Intracranial Hemorrhage in Patients with Hemophilia in the Prophylaxis Era.

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3388-3388
Author(s):  
Char Witmer ◽  
Rodney Pressley ◽  
Roshni Kulkarni ◽  
J. Michael Soucie ◽  
Catherine Scott Manno
Keyword(s):  
Mortality Rate ◽  
Reference Group ◽  
Univariate Analysis ◽  
P Value ◽  
Severe Hemophilia ◽  
Clinical Factors ◽  
Factors Associated ◽  
Annual Visit ◽  
Nested Case Control

Abstract Objective: With a mortality rate of 20%, intracranial hemorrhage (ICH) accounts for the highest number of deaths from bleeding in patients with hemophilia and is a common cause of long-term disability. We performed a nested case-control study within a cohort of males with hemophilia enrolled in the Centers for Disease Control and Prevention (CDC) Universal Data Collection (UDC) project. The study objective was to identify rates and risk factors associated with ICH in the modern era of prophylaxis. Patients and methods: Study participants were males with hemophilia A or B, enrolled in the CDC UDC project, 2 years or older, who had an initial visit, and at least one follow up event between May 1998 and March 2008. Patients were followed from the initial visit until their study termination event, defined as an ICH reported during a subsequent annual visit, death, or the latest annual visit held during the study period. Cases were patients who after UDC enrollment either had an ICH or whose cause of death was from an ICH. The following clinical factors were examined for an association with ICH: hemophilia type, severity level, prior ICH, presence of an inhibitor, treatment with prophylaxis, HIV status, chronic hepatitis B, hepatitis C, alcohol abuse, elevated prothrombin time, ethnicity and age. Data analysis was conducted using SAS 9.2 (SAS Institute, Cary, NC). Factors associated with ICH were identified using a nested case control design. Interaction effects were assessed using the Breslow-Day Test for homogeneity of the odds ratios. The independent association between prophylaxis and ICH was assessed using logistic regression. All hypothesis testing was two tailed with odds ratios and confidence intervals reported. Results: During the study period 10,262 patients were identified who met the inclusion criteria. Of these, 199 (1.9%) experienced an ICH. Based on patient follow up time (mean 4.9 +/−2.46 years) the incidence rate was 3.9 per thousand patient years. Thirty-nine of the 199 ICH cases died from the event, resulting in a mortality rate of 19.6%. In 148 (74%) of the ICH cases, the subjects had severe hemophilia. See table 1 for univariate analysis of all patients. Table 1: Clinical factors associated with ICH for all patients in the cohort, N=10,262 (univariate analysis) Clinical Factors Odds Ratio (95% CI) P-Value *Reference group White (non-Hispanic). **Reference group age 10–15 years. Prior ICH 3.62 (2.66–4.92) <0.001 Severe Hemophilia 3.25 (2.01–5.25) <0.001 High Titer Inhibitor 4.01 (2.40–6.71) <0.001 Hepatitis C 1.73 (1.30–2.29) <0.001 Black (non-Hispanic)* 2.07 (1.46–2.96) <0.001 Age 2-9 years** 1.85 (1.14–2.99) 0.01 Age >41 years** 2.17 (1.34–3.50) 0.001 For the entire cohort, prophylaxis use was not associated with a statistically significantly reduced risk of ICH (0.83 (0.61–1.15) p=0.26). However, further analysis (see table 2), restricted to patients with severe hemophilia, demonstrated a protective effect of prophylaxis use that was limited only to patients who did not have an inhibitor and who were not infected with HIV. Table 2: Clinical factors independently associated with ICH among 5,485 patients with severe hemophilia (multivariate analysis) Clinical Factors Odds Ratio (95% CI) P-Value **Reference group age 10–15 years. Prophylaxis no inhibitor 0.50 (0.32–0.77) 0.002 Prophylaxis no HIV 0.52 (0.34–0.81) 0.004 Prior ICH 3.24 (2.27–4.64) <0.0001 Chronic Hepatitis B 2.99 (1.03–8.63) 0.043 Age 2–9 years** 1.92 (1.05–3.51) 0.034 Conclusion: This study demonstrates that patients with severe hemophilia who use prophylaxis and are not HIV positive and do not have an inhibitor experience a 50% risk reduction for ICH. This study confirms the previously identified risk factors for ICH including severity of disease, prior ICH, young age and the presence of an inhibitor. The strongest predictor for ICH was a history of ICH before enrollment in the UDC. Unfortunately even in the age of widely available prophylactic therapy, the mortality rate from ICH remains quite high at 19.6%.

Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4321-4321 ◽  
Author(s):  
Gabriela Rondon ◽  
Rima M Saliba ◽  
Julianne Chen ◽  
Celina Ledesma ◽  
Amin M. Alousi ◽  
...  
Keyword(s):  
Stem Cell ◽  
Weight Gain ◽  
Stem Cell Transplantation ◽  
Advanced Disease ◽  
Univariate Analysis ◽  
Disease Status ◽  
Factors Associated ◽  
Transplant Patients ◽  
Major Organ

Abstract Background: Fluid retention/overload (FO) is common during hospitalization for allogeneic stem cell transplantation (ASCT) and is associated with weight gain (WG), edema, and other symptoms such as shortness of breath. It is unknown if symptomatic FO impacts transplant outcomes. We hypothesized that FO is associated with non-relapse mortality (NRM) and worse survival after ASCT. Methods: FO was scored by an independent team using the following criteria: grade 1 - asymptomatic weight gain <10% from baseline requiring occasional diuretics; grade 2 -symptomatic and or WG 10%-20% from baseline requiring continuing diuretics grade 3 WG ≥20% from baseline requiring further treatment (dialysis) with or without renal, pulmonary, and or cardiac dysfunction; grade 4 - major organ dysfunction. Results: We initially evaluated FO in a cohort of haploidentical transplant patients with hematologic malignancies (N=145) all treated with identical conditioning (melphalan-based) regimen, and received predominantly a bone marrow graft (94%). The median follow-up was 18 months. 43% of patients were in CR1/2. Median age for this group was 45 years (range 19-69), 58% were males. Median weight was 82 kg (37-180kgs) at study entry before starting the preparative regimen. The median creatinine was 0.75 with >1.0 mg/dl in 16% of the patients. Median DLCO was 70 and EF was normal (>40%) in all except 2 patients. Thirty patients (21%) developed ≥ grade 2 FO. Factors associated with Day100 NRM were ≥ grade 2 FO (HR 15, CI 4.2-55, p<0.001), cr>1 (HR 4.7, CI 1.6-14, p=0.005) and age>55 (HR 4.5, CI 1.5-13, p=0.008) by univariate analysis. In multivariate analysis (MVA) factors that retained significance were FO ≥ grade 2 (HR 13.1, CI 3.4-50, p<0.001) and cr>1 at study entry (HR 3.5, CI 1.1-11, p=0.03). We verified the prognostic value of FO in a separate cohort of HLA matched transplants [N= 449, 190 matched related donor (MRD) and 259 matched unrelated donor (MUD)] with AML/MDS treated with fludarabine and busulfan conditioning. The median follow-up for this group was 23 months. The median age was 58 years (range 18-77). 42% were in CR1/2 at transplant. 68% had a peripheral blood graft. Median weight was 81kg (47-170). Median creatinine at transplant was 0.8, 19% had >1 mg/dl. Median DLCO was 71 and EF was normal (>40%) in all except 2 patients. Significant factors associated with Day100 NRM by univariate analysis, were FO ≥ grade 2 (HR 11, CI 4.5-25, p<0.001) and advanced disease status at transplant (not in CR1/2) (HR 3.5, CI 1.2-10, p=0.02). By MVA, FO≥ grade 2 was the only factor highly associated with Day100 NRM (HR 34, CI 7.2-158, p<0.001), and advanced disease status in patients with FO<2 (HR 5, CI 1.1-22, p=0.03). Worse NRM translated in significantly worse 3-years survival for patients with FO in both haploidentical and HLA matched transplants group (Figure). Haploidentical transplant patients with FO≥2 were more likely to have weight < 80 kgs(57% vs.33%, p=0.02), but there was no such correlation in the matched transplants group. Conclusions: FO should be considered an important adverse event post ASCT. Grade 2 or greater FO is strongly associated with NRM and worse survival. FO is likely related to the rate of intravenous fluid administration and other factors (oncotic pressure, capillary leak and major organ dysfunction post-transplant). Caution is warranted to prevent excessive hydration and weight gain in the early post-transplant period. Other factors potentially associated with weight gain will be evaluated. Figure 1. (A) NRM and (B) OS in haploidenticaltransplants; (C) NRM and (D) OS in matched transplants. Figure 1. (A) NRM and (B) OS in haploidenticaltransplants; (C) NRM and (D) OS in matched transplants. Disclosures Alousi: Therakos, Inc: Research Funding.

Relationship of lymphocyte and eosinophil counts and immune-related adverse events in recipients of programmed death-1 (PD-1) inhibitor therapy: A single-center retrospective analysis.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e14586-e14586 ◽  
Author(s):  
Adam Diehl ◽  
Mark Yarchoan ◽  
Ting Yang ◽  
Blake Scott ◽  
Burles Avner Johnson ◽  
...  
Keyword(s):  
Adverse Events ◽  
Univariate Analysis ◽  
Retrospective Chart Review ◽  
Absolute Lymphocyte Count ◽  
Multivariate Regression Analysis ◽  
Tumor Type ◽  
Increased Risk ◽  
Investigational Therapies ◽  
Clinically Significant ◽  
Eosinophil Counts

e14586 Background: Inhibition of the PD-1 checkpoint can cause immune activation in non-target tissues, resulting in immune-related adverse events (irAE) in up to 50% of patients. Biomarkers that are associated with irAEs in patients treated with PD-1 inhibitors may have implications for patient selection and clinical management. Methods: We performed an IRB-approved retrospective chart review of adult solid tumor patients treated with nivolumab or pembrolizumab at a single institution from January 2015 until November 2016. Patients were excluded if concurrently receiving investigational therapies, or on unreported clinical trials. Data were collected on treatment history, leukocyte counts, and irAE, defined as adverse events with a potential immunologic basis with grading performed using CTCAE v.4.0. Results: 172 patients were included (lung n = 54; melanoma n = 61; kidney n = 25; esophageal n = 12; bladder n = 8; other tumors n = 12) with median age 67. 18% were treated with concurrent ipilimumab. 31% experienced an adverse event of any grade with a mean time to develop an irAE of 3.5 months. Of those with an irAE, 85% required treatment, 68% were grade ≥ 2, 32% were grade 3 or 4 and 35% required therapy discontinuation due to the irAE. In univariate analysis, a higher ALC at both the start of therapy and at 1 month was associated with increased risk of an irAE of grade ≥ 2 (p < 0.05). A higher absolute lymphocyte count (ALC) or higher absolute eosinophil count (AEC) at 1 month into therapy was associated with increased risk of all irAE (p < 0.05) as well as irAE requiring treatment (p < 0.05). In addition, in a multivariate regression analysis including age, race, tumor type, prior chemotherapy, prior radiation, and concurrent ipilimumab therapy, an ALC > 2000 at the start of therapy was a significant predictor of irAE of grade ≥ 2 (p < 0.05 and OR 2.0), as was an ALC > 2000 at 1 month into therapy (p < 0.05 and OR 1.86). Conclusions: These results suggest that high lymphocyte and eosinophil counts early in the course of anti-PD1 therapy may be associated with a higher risk for clinically significant irAE.

Factors associated with non-retention in HIV care in an era of widespread antiretroviral therapy

2016 ◽  
Vol 28 (7) ◽  
pp. 679-684 ◽  
Author(s):  
Sarah O’Connell ◽  
Anna O’Rourke ◽  
Eileen Sweeney ◽  
Almida Lynam ◽  
Corinna Sadlier ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Drug Users ◽  
Univariate Analysis ◽  
Multivariable Analysis ◽  
Structured Interview ◽  
Hiv Care ◽  
Factors Associated ◽  
Retention In Hiv Care ◽  
Sex With Men ◽  
Hiv 1

In an era of antiretroviral therapy (ART) for all HIV-1-infected patients, our primary aim was to describe prevalence and characteristics of patients disengaged from care at an urban ambulatory HIV clinic. We conducted a nested case–control study. All patients who disengaged from care (defined as being lost to follow-up for at least one year) from 2007 to 2014 inclusive were identified. Cases were matched to controls in a 1:4 ratio. A total of 1250 cases were included; 250/2289 (10.9%) of patients attending our HIV clinic disengaged from 2007 to 2014. One hundred and twenty-six (50.4%) were heterosexual, 81 (32.4%) were men who have sex with men and 40 (16%) were intravenous drug users. On univariate analysis only, patients with heterosexual risk were more likely to disengage from care (50.4% vs. 33.7%, p: <0.001). Those who disengaged were younger, mean age of 39 (p: <0.001). A higher proportion of patients who disengaged from care was not receiving ART and did not have a suppressed HIV-1 viral load (p: <0.001). On multivariable analysis, Irish patients were less likely to disengage from HIV care (odds ratio: 0.567, p: 0.002). Factors associated with non-retention in HIV care have been identified. A semi-structured interview of those patients who re-engaged will take place to further examine reasons for disengagement from care.

Sign in / Sign up

Export Citation Format

Share Document